Novo Nordisk cut its 2025 guidance and outgoing CEO blames the compounding market for it.
Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook
July 29, 2025
You may also like
Indices by TradingView
IKEA hot dog raises questions about Costco’s $1.50 deal
February 10, 2026
Why Valaris Stock Surged Today
February 9, 2026
Categories
Indices by TradingView



